• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多标准决策分析在评估以药物为导向的干预措施价值中的应用:一项文献综述。

The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review.

作者信息

Su Pengli, Zhi Kai, Xu Huanhuan, Xiao Jing, Liu Jun, Wang Zhong, Liu Qiong, Yu Yanan, Dang Haixia

机构信息

Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.

China Academy of Chinese Medical Sciences, Beijing, China.

出版信息

Front Pharmacol. 2024 Apr 24;15:1245825. doi: 10.3389/fphar.2024.1245825. eCollection 2024.

DOI:10.3389/fphar.2024.1245825
PMID:38720775
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11076741/
Abstract

Multi-Criteria Decision Analysis (MCDA) has gained increasing attention in supporting drug risk-benefit assessment, pricing and reimbursement, as well as optimization of clinical interventions. The objective of this study was to systematically collect and categorize evaluation criteria and techniques of weighting and scoring of MCDA for drug value assessment. A systematic review of the literature was conducted across seven databases to identify articles utilizing the MCDA frameworks for the evaluation of drug value. Evaluation criteria mentioned in the included studies were extracted and assigned to 5 dimensions including clinical, economic, innovative, societal and humanistic value. A descriptive statistical analysis was performed on the identified drug value evaluation criteria, as well as the weighting and scoring techniques employed. The more a criterion or technique were mentioned in articles, the more important we consider it. Out of the 82 articles included, 111 unique criteria were identified to evaluate the value of drug. Among the 56 unique criteria (448 times) used to measure clinical value, the most frequently mentioned were "comparative safety/tolerability" (58 times), "comparative effectiveness/efficacy" (56 times), "comparative patient-perceived health/patient reported outcomes" (37 times), "disease severity" (34 times), and "unmet needs" (25 times). Regarding economic value measurement, out of the 20 unique criteria (124 times), the most frequently utilized criteria were "cost of intervention" (17 times), "comparative other medical costs" (16 times), and "comparative non-medical costs" (18 times). Out of the 10 criteria (18 times) for assessing innovative value, "a novel pharmacological mechanism" was the most frequently mentioned criterion (5 times). Among the 22 criteria (73 times) used to measure societal value, "system capacity and appropriate use of intervention" was the most frequently cited criterion (14 times). Out of the 3 criteria (15 times) utilized to measure humanistic value, "political/historical/cultural context" was the most frequently mentioned criterion (9 times). Furthermore, 11 scoring and 11 weighting techniques were found from various MCDA frameworks. "Swing weighting" and "a direct rating scale" were the most frequently used techniques in included articles. This study comprehensively presented the current evaluation dimensions, criteria, and techniques for scoring and weighting in drug-oriented MCDA articles. By highlighting the frequently cited evaluation criteria and techniques for scoring and weighting, this analysis will provide a foundation to reasonably select appropriate evaluation criteria and technique in constructing the MCDA framework that aligns with research objectives.

摘要

多标准决策分析(MCDA)在支持药物风险效益评估、定价与报销以及临床干预优化方面受到了越来越多的关注。本研究的目的是系统收集和分类用于药物价值评估的MCDA评估标准以及加权和评分技术。我们在七个数据库中对文献进行了系统综述,以识别利用MCDA框架评估药物价值的文章。提取纳入研究中提到的评估标准,并将其分配到临床、经济、创新、社会和人文价值五个维度。对识别出的药物价值评估标准以及所采用的加权和评分技术进行了描述性统计分析。文章中提及某一标准或技术的次数越多,我们认为其越重要。在纳入的82篇文章中,共识别出111条评估药物价值的独特标准。在用于衡量临床价值的56条独特标准(共提及448次)中,最常被提及的是“比较安全性/耐受性”(58次)、“比较有效性/疗效”(56次)、“比较患者感知健康/患者报告结局”(37次)、“疾病严重程度”(34次)以及“未满足需求”(25次)。在衡量经济价值方面,在20条独特标准(共提及124次)中,最常使用的标准是“干预成本”(17次)、“比较其他医疗成本”(16次)以及“比较非医疗成本”(18次)。在评估创新价值的10条标准(共提及18次)中,“新的药理机制”是最常被提及的标准(5次)。在用于衡量社会价值的22条标准(共提及73次)中,“系统能力和干预的合理使用”是最常被引用的标准(14次)。在用于衡量人文价值的3条标准(共提及15次)中,“政治/历史/文化背景”是最常被提及的标准(9次)。此外,从各种MCDA框架中发现了11种评分技术和11种加权技术。“摆动加权”和“直接评分量表”是纳入文章中最常使用的技术。本研究全面呈现了当前以药物为导向的MCDA文章中的评估维度、标准以及评分和加权技术。通过突出经常被引用的评估标准以及评分和加权技术,本分析将为在构建与研究目标相符的MCDA框架时合理选择合适的评估标准和技术提供基础。

相似文献

1
The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review.多标准决策分析在评估以药物为导向的干预措施价值中的应用:一项文献综述。
Front Pharmacol. 2024 Apr 24;15:1245825. doi: 10.3389/fphar.2024.1245825. eCollection 2024.
2
Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review.多标准决策分析和价值框架中用于评估罕见病疗法的标准及评分函数:一项系统文献综述
Pharmacoecon Open. 2021 Dec;5(4):605-612. doi: 10.1007/s41669-021-00271-w. Epub 2021 May 18.
3
MULTI-CRITERIA DECISION ANALYSIS AS A DECISION-SUPPORT TOOL FOR DRUG EVALUATION: A PILOT STUDY IN A PHARMACY AND THERAPEUTICS COMMITTEE SETTING.多准则决策分析作为药物评估的决策支持工具:在药房和治疗学委员会环境中的初步研究。
Int J Technol Assess Health Care. 2018 Jan;34(5):519-526. doi: 10.1017/S0266462318000569. Epub 2018 Oct 23.
4
Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology.患者参与反思性多准则决策分析以辅助肿瘤学决策制定。
Int J Technol Assess Health Care. 2019 Jan;35(1):56-63. doi: 10.1017/S0266462318003641. Epub 2019 Feb 7.
5
Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).平衡医学创新不同阶段的成本与效益:多标准决策分析(MCDA)的系统评价
BMC Health Serv Res. 2015 Jul 9;15:262. doi: 10.1186/s12913-015-0930-0.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA).通过多准则决策分析(MCDA)识别西班牙耐药性癫痫(DRE)患者局灶性发作(FOS)治疗中的关键未满足需求和价值驱动因素。
Epilepsy Behav. 2021 Sep;122:108222. doi: 10.1016/j.yebeh.2021.108222. Epub 2021 Aug 6.
8
Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.用于卫生技术评估的多标准决策分析(MCDA):昆士兰卫生部门的经验
Aust Health Rev. 2019 Oct;43(5):591-599. doi: 10.1071/AH18042.
9
Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?罕见病药物卫生技术评估中的多标准决策分析(MCDA)模型——系统文献综述。方法学发展的下一步?
Front Public Health. 2018 Oct 15;6:287. doi: 10.3389/fpubh.2018.00287. eCollection 2018.
10
Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA).运用多标准决策分析(MCDA)加强欧洲多病共存患者综合护理的证据基础。
BMC Health Serv Res. 2018 Jul 24;18(1):576. doi: 10.1186/s12913-018-3367-4.

本文引用的文献

1
[Expert consensus on core indicators for lifecycle value assessment of Chinese patent medicine].[中成药生命周期价值评估核心指标专家共识]
Zhongguo Zhong Yao Za Zhi. 2023 Oct;48(19):5389-5396. doi: 10.19540/j.cnki.cjcmm.20230516.501.
2
Health technology assessment to inform decision making in China: progress, challenges, and sustainability.卫生技术评估在中国决策制定中的应用:进展、挑战与可持续性。
BMJ. 2023 Jun 15;381:e068910. doi: 10.1136/bmj-2021-068910.
3
Applying reflective multicriteria decision analysis to understand the value of therapeutic alternatives in the management of gestational and peripartum anaemia in Spain.
应用反思性多准则决策分析来了解在西班牙妊娠和围产期贫血管理中治疗选择的价值。
BMC Pregnancy Childbirth. 2022 Feb 25;22(1):157. doi: 10.1186/s12884-022-04481-w.
4
Prioritizing Healthcare Interventions: A Comparison of Multicriteria Decision Analysis and Cost-Effectiveness Analysis.优先医疗干预措施:多准则决策分析与成本效益分析比较。
Value Health. 2022 Feb;25(2):268-275. doi: 10.1016/j.jval.2021.08.008. Epub 2021 Sep 23.
5
Criteria and Scoring Functions Used in Multi-criteria Decision Analysis and Value Frameworks for the Assessment of Rare Disease Therapies: A Systematic Literature Review.多标准决策分析和价值框架中用于评估罕见病疗法的标准及评分函数:一项系统文献综述
Pharmacoecon Open. 2021 Dec;5(4):605-612. doi: 10.1007/s41669-021-00271-w. Epub 2021 May 18.
6
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).多利益相关者多准则决策分析孤儿药的报销(FinMHU-MCDA 研究)。
Orphanet J Rare Dis. 2021 Apr 26;16(1):186. doi: 10.1186/s13023-021-01809-1.
7
Comprehensive Benefit-Risk Assessment of Noninferior Treatments Using Multicriteria Decision Analysis.综合效益-风险评估非劣效治疗的多准则决策分析。
Value Health. 2020 Dec;23(12):1622-1629. doi: 10.1016/j.jval.2020.09.002. Epub 2020 Oct 29.
8
Advancing structured decision-making in drug regulation at the FDA and EMA.推进 FDA 和 EMA 药物监管中的结构化决策。
Br J Clin Pharmacol. 2021 Feb;87(2):395-405. doi: 10.1111/bcp.14425. Epub 2020 Jul 1.
9
Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice.开发一种多准则决策分析框架,用于评估和定位肿瘤治疗在临床实践中的地位。
JCO Oncol Pract. 2020 Mar;16(3):e298-e305. doi: 10.1200/JOP.19.00487.
10
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.糖尿病性黄斑水肿管理中的多利益相关者多标准决策分析:MULTIDEX-EMD研究。
Pharmacoecon Open. 2020 Dec;4(4):615-624. doi: 10.1007/s41669-020-00201-2.